Our findings suggest that MRPL37 could serve as a potential therapeutic target for liver cancer, offering a foundation for the development of treatment strategies aimed at disrupting mitochondrial function and reprogramming tumor metabolism. This evidence concerns the gene MRPL37 and neoplasm.